Research Reports

Summary

Harvard Bioscience reported Q1 FY2026 revenue of $20.8M, down 4.7% year-over-year, reflecting continued pressure from academic and distributor demand; however, operating and net losses narrowed significantly versus Q1 FY2025 due to improved cost discipline and absence of prior-year non-recurring charges.

Key takeaways

Revenue declined 4.7% to $20.8M, driven by lower sales to academic research institutions in the Americas and distributors in Asia Pacific.

Gross profit remained flat at $12.2M year-over-year, while gross margin improved to 59.0% — primarily due to favorable product mix.

Operating income improved to -$1.2M from -$49.7M, reflecting structural cost reductions and consolidation of the global operating footprint.

Net income improved to -$3.4M from -$50.3M, with diluted EPS rising to -$0.77 from -$1.14, supported by higher gross margin and disciplined operating expense management.

Full analysis

Revenue Performance

Revenue for Q1 FY2026 totaled $20.8M, a 4.7% decline from $21.8M in Q1 FY2025. This decrease was primarily due to lower sales from academic research institutions in the Americas and distributors in Asia Pacific — consistent with ongoing uncertainty regarding the level and timing of U.S. funding, which continues to affect customer purchasing behavior.

Gross Profit and Margin

Operating Income and Expense Discipline

Operating income improved to -$1.2M from -$49.7M in Q1 FY2025. This substantial improvement reflects the absence of the prior-year goodwill impairment charge and sustained progress on operational efficiency initiatives. These include the discontinuation of non-strategic products, consolidation of the global operating footprint, and reduction of headcount in Europe and North America — actions aligned with Project Viking.

HBIO · Harvard Bioscience, Inc.